Expertise in
1
conditions

Piotr Korbal

75 Ujejskiego St, 
Bydgoszcz, KP, PL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
75 Ujejskiego St, 
Bydgoszcz, KP, PL 

Overview

Piotr Korbal practices in Bydgoszcz, Poland. Mr. Korbal is highly rated in 1 condition, according to our data. His top areas of expertise are Infant Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome (ARDS), Tetanus, and Premature Infant.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

75 Ujejskiego St, Bydgoszcz, KP 85168, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection
An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection
Enrollment Status: Recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drug: Zanamivir
Study Phase: Phase 2
A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)
A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Combination product, Biological
Study Phase: Phase 1/Phase 2
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Infants
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Infants
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Combination product
Study Phase: Phase 2
A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome
A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome
Enrollment Status: Completed
Publish Date: April 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
Enrollment Status: Terminated
Publish Date: July 23, 2019
Intervention Type: Combination product, Device
Study Phase: Phase 2
View 4 Less Clinical Trials

15 Total Publications

Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants.
Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants.
Journal: Vaccine
Published: September 15, 2025

Frequently Asked Questions about Piotr Korbal

Is Piotr Korbal a top-rated expert for Infant Respiratory Distress Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Piotr Korbal is classified as an Advanced expert for Infant Respiratory Distress Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Piotr Korbal participate in research or clinical trials?

Yes. Piotr Korbal has published 15 articles and abstracts on conditions like Infant Respiratory Distress Syndrome. You can view a list of Piotr Korbal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Korbal's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile